POM: Prescription only medicine
Risk Management Educational Material
In addition to the Summary of Product Characteristics, this leaflet was developed by the marketing authorisation holder to inform you about all delicate issues potentially arising from Leflunomide medac therapy. Counselling patients on important risks associated with Leflunomide medac therapy and appropriate precautions when using the medicine is required.
For Healthcare Professionals
Theaterstrasse 6, 22880 Wedel, Germany
+44 (0)1786 458032
+44 (0)1786 458086